

## WORKSHEET: Expedited Review

|           |  | A      | dvent Health  |   |  |   |  |   |  |
|-----------|--|--------|---|---|--|---|--|---|--|
|           |  |        | Orlando   |   | Document No.:  | Edition No.:                                      | Effective Date:  | Page:   |  |
|           |  |        |   | _   | HRP-424  | 002   | 08 Nov 2019  | 1 of 2  |  |
| This work | sheet is u   | sed    | to determine whether non  | -exempt <human res<="" td=""><td>earch&gt; can be revie</td><td>wed using the exped</td><td>lited procedure</td><td></td></human> | earch> can be revie  | wed using the exped                               | lited procedure  |   |  |
| ®         |  | 000    |   |   |  | nou using the exped                               |  |   |  |
| -         | clusion c  | riter  | ia: (If any are true, the res   | earch cannot be revie   | wed using the expe   | dited procedure)                                  |  |   |  |
|           |  |        | is <classified research=""></classified>  |   |  |   |  |   |  |
| 1.2       |  |        | is DOD-regulated and inv  | volves < Prisoners> as  | subjects   |   |  |   |  |
| 2. Ris    |  |        | of the following must be tru  |   | ,<br>,   |   |  |   |  |
|           |  |        | wing are true:  |   |  |   |  |   |  |
|           | 2.1.1  |        | The research in its curren<br>liability, or damage financ<br>breach of confidentiality  | nt state presents no mo<br>cial standing, employal  | ore than <minimal r<br="">bility, insurability, re</minimal> | isk> to subjects, inclu<br>outation, or be stigma | uding <minimal risk=""> of<br/>tization related to invas</minimal> | f criminal or civil<br>sion of privacy and                    |  |
|           | 2.1.2  |        | One of the following is tru<br>The research does no<br>A prisoner representa  | ot involve <prisoners></prisoners>  |  | irs with the minimal ri                           | sk determination   |   |  |
| 2.2       | The activ  | itv fa | alls into (8)(b), (HDE), (MM  |   |  |   |  |   |  |
|           |  | 5      | e 60364-60367, November 9, 199  | , , ,   |  |   |  |   |  |
|           | 3  |        | nuing review of research t  |   | edures in one or mo  | ore of the following:                             |  |   |  |
|           | (1)(a)   |        | Clinical studies of drugs f   |   |  |   |  |   |  |
|           | (1)(b)   |        | Clinical studies on medica  |   |  |   |  |   |  |
|           | (2)(a)   |        | Collection of blood sampl<br>110 pounds, where the ar<br>2 times per week (see Fo   | otnote 1)   |  |   |  |   |  |
|           | (2)(b)   |        | Collection of blood sampl<br>drawn may not exceed th<br>per week (see Footnote 2  | es by finger stick, hee<br>e lesser of 50 ml or 3<br>2)   | l stick, ear stick, or v<br>ml/kg in an 8 week j             | venipuncture from oth<br>period and collection    | er adults and <childrer<br>may not occur more fre</childrer<br>    | <ol> <li>where the amount<br/>quently than 2 times</li> </ol> |  |
|           | (3)  |        | Prospective collection of I   | biological specimens f  | or research purpose  | es by noninvasive me                              | ans (see Footnote 3)   |   |  |
|           | (4)  |        | Collection of data through<br>practice, excluding proces  | dures involving x-rays  | or microwaves (see   | e Footnote 4)                                     |  | -   |  |
|           | (5)  |        | Research involving mater  |   |  |   |  | ch purposes   |  |
|           | (6)  |        | Collection of data from vo  |   |  |   | oses.  |   |  |
|           | (7)(a)   |        | Research on individual or group characteristics or behavior (see Footnote 5)<br>Research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance |   |  |   |  |   |  |
|           | (7)(b)   |        | methodologies   | ey, interview, orai hist  | ory, locus group, pr   | oyiani evaluation, nu                             | IIIali iaciois evaluation,   | or quality assurance  |  |
|           | (NR)   |        | Research not conducted,   | supported or otherwis   | se subject to regulat  | ion by any US federal                             | I department or agency   | and not FDA-regulated   |  |
| 3.2       | Continuing review of an activity previously approved by the convened IRB where one of the following is true: |        |   |   |  |   |  |   |  |
|           | (8)(a)   |        | The research is permane<br>interventions at the site; a<br>follow-up" means interact<br>identifiable information fro<br>in the research protocol  | and (iii) the research re   | emains active only fo  | nr lona-term follow-un                            | of subjects at the site  | where "long-term  |  |
|           | (8)(b)   |        | No subjects have ever be  |   |  |   | fied at any site   |   |  |
|           | (8)(c)   |        | The remaining research a  | activities at the site are  | e limited to data ana  | lysis   |  |   |  |
|           | (9)  |        | The research is not condu<br>do not apply, the IRB has<br>and no additional risks ha  | determined and docu<br>ave been identified at a   | gational new drug a<br>mented at a conver<br>any site        | pplication or investigated meeting that the r     | ational device exemption esearch involves no gre                   | n, the above categories<br>eater than minimal risk,           |  |
|           | (HDE)  |        | The activity is a non-rese  | arch clinical HDE use   | (see Footnote 6)   |   |  |   |  |
| 3.3       |  |        | ations of an activity previo  | J I I J   | IRB where one of th  | e following is true:                              |  |   |  |
|           | (MM1)  |        | All of the following are tru  |   |  |   |  |   |  |
|           |  |        |   | cation adds no more th  |  |   |  |   |  |
|           |  |        |   | substantial alteration  |  |   |  |   |  |
|           | (1 41 40)  |        |   | rocedures fall into cate  |  |   |  |   |  |
|           | (MM2)  |        | The modification is the ac  |   |  |   |  |   |  |
|           |  |        |   |   |  |   | No Expedited Review"   |   |  |
|           |  |        | (MM2).2 X The researce (MM2).3 All investigation  |   |  |   |  |   |  |
|           |  |        |   |   |  |   | ver>, merit convened IR  | R review  |  |
| 4. Not    |  |        |   | IO ULIEI ISSUES, WHICH  |  | - VESIGIIAIEU KEVIEN                              |  |   |  |
| 4. NO     |  |        |   |   |  |   |  |   |  |
|           |  |        |   |   |  |   |  |   |  |

| Advent Health |
|---------------|
|---------------|

## WORKSHEET: Expedited Review

Edition No.:

Document No.: HRP-424 Effective Date:

08 Nov 2019

Page:

2 of 2

## 5. Footnotes

5.1 Each access of a indwelling line is one venipuncture.

| 0.1 |  |
|-----|--|
| 5.2 | When assessing risk consider the age, weight, and health of the subjects, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected.  |
| 5.3 | Examples: (a) hair and nail clippings in a non-disfiguring manner; (b) deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction; (c) permanent teeth if routine patient care indicates a need for extraction; (d) excreta and external secretions (including sweat); (e) uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum-base or wax or by applying a dilute citric solution to the tongue; (f) placenta removed at delivery; (g) anniotic fluid obtained at the time of rupture of the membrane prior to or during labor; (h) supra- and subgingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth and the process is accomplished in accordance with accepted prophylactic techniques; (i) mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings; (j) sputum collected after saline mist nebulization. |
| 5.4 | Examples: (a) physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the subject or an invasion of the subject's privacy; (b) weighing or testing sensory acuity; (c) magnetic resonance imaging; (d) electrocardiography, electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow, and echocardiography; (e) moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.  |
| 5.5 | Including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior  |
| 5.6 | Guidance for HDE Holders, Institutional Review Boards (IRBs), Clinical Investigators, and FDA Staff - Humanitarian Device Exemption (HDE) Regulation: Questions and Answers Question See question and answer 46.   |
|     |  |